Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 4/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31380329 | 0.83 | MLYCD (0.43) | KMT2AGRM5GABRA1GABRG2GABRB3 | |
| SCHEMBL13676427 | 0.81 | HSP90AA1 (0.51) | KMT2AMAPTGRM5SMN1; SMN2NPC1 | |
| SCHEMBL25094798 | 0.81 | ESRRG (0.41) | KMT2ARAB9ATRPV1 | |
| SCHEMBL3203433 | 0.79 | P4HTM (0.53) | KMT2AMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL9906446 | 0.79 | KMT2A (0.46) | KMT2AEPHX2NR1H4MAPTGABRA1 | |
| SCHEMBL25972065 | 0.79 | KMT2A (0.35) | KMT2AGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL10034528 | 0.78 | KMT2A (0.44) | KMT2AMAPTGABRA1GABRG2GABRB3 | |
| SCHEMBL3486437 | 0.78 | KMT2A (0.44) | KMT2AMAPTGABRA1GABRG2GABRB3 | |
| SCHEMBL2678960 | 0.78 | KMT2A (0.68) | KMT2AEPHX2NR1H4MAPTGABRA1 | |
| SCHEMBL25094703 | 0.77 | SCN9A (0.37) | KMT2AGRM5RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | BEIGENE, LTD. (KY) | 2023-08-15 | — | — | US | disclosed |
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | BEIGENE, LTD. (KY) | 2023-08-15 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2023-04-20 | — | — | US | disclosed |
| US-20100125073-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | US | disclosed |
| US-20100029614-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-7598261-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7585888-B2 | Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | disclosed |
| US-20090054514-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-02-26 | — | — | US | disclosed |
| US-7384947-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2008-06-10 | — | — | US | disclosed |
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CALIXA THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-7351735-B2 | Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | KMT2A 757/4885EPHX2 2805/4885NR1H4 2612/4885 |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | KMT2A 4174/4885EPHX2 1868/4885NR1H4 3219/4885 |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | KMT2A 757/4885EPHX2 2805/4885NR1H4 2612/4885 |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | KMT2A 68/4885EPHX2 3444/4885NR1H4 2496/4885 |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | BCLAF1, EED, BCL3 | KMT2A 84/4885EPHX2 597/4885NR1H4 1426/4885 |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | KMT2A 757/4885EPHX2 2805/4885NR1H4 2612/4885 |
| US-20100125073-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BCOR, BRDT, TPMT | KMT2A 816/4885EPHX2 2660/4885NR1H4 2122/4885 |
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CHAT, GRIN2C, GRIN2A | KMT2A 2128/4885EPHX2 359/4885NR1H4 745/4885 |
| US-20090054514-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | ETV6, MKI67, PAH | KMT2A 1353/4885EPHX2 3302/4885NR1H4 1237/4885 |
| US-20100029614-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | KMT2A 2918/4885EPHX2 868/4885NR1H4 81/4885 |
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | PIK3CD, PIK3R5, PIK3CA | KMT2A 2686/4885EPHX2 4285/4885NR1H4 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.